InvestorsHub Logo

Steady_T

09/20/17 9:05 PM

#121023 RE: nidan7500 #120992

The bad news is we get silence, which is simply not sustainable.



Sure it's sustainable, it's just very painful

dadofmarcmax

09/20/17 11:42 PM

#121047 RE: nidan7500 #120992

Wonderful post, nidan, and thanks for all of your insights. I remain firm in my belief that there is a common pathophysiological mechanism involving chronic neuroinflammation that, depending on age of onset, genotype, environmental variables, etc., result in many seemingly different neurological conditions. Anavex is the first to take this route in the approach to neurodegenerative conditions.

I look forward to the day where I foresee how 2-73 will advance clinical epileptology.

bas2020

09/21/17 12:08 AM

#121050 RE: nidan7500 #120992

I firmly believe that the delay with the Alz trial has everything to do with the FDA trial design under the new regs. If not for that, the trial would have begun by June, according to Macfarlane's comments from January.